Nashville, Tennessee
Cancer clinical trials in Nashville, TN
344 cancer studies are recruiting participants at sites in Nashville as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Nashville at a glance
- 344 studies are recruiting at a site in Nashville.
- By phase: Early Phase 1 (1), Phase 1 (90), Phase 1/2 (83), Phase 2 (60), Phase 2/3 (10), Phase 3 (76), Phase 4 (4), No phase (4), Observational (16). Studies of devices and behavioral approaches have no phase.
- By sponsor: industry (286), university, hospital or other (48), government (10).
- By research area: Breast Cancer (116), Lung Cancer (100), Lymphoma (58), Prostate Cancer (32), Melanoma (20), Pancreatic Cancer (18).
- Most recent update to one of these records: November 16, 2026.
Breast cancer studies recruiting in Nashville
Basic details from each study's public record (the 30 most recently updated of 344). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Boehringer Ingelheim
- Study sites
- SCRI Oncology Partners · Tennessee Oncology, Pllc
- Registry record
- NCT06324357 · updated
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Vanderbilt Breast Center at One Hundred Oaks
- Registry record
- NCT05422794 · updated
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Phase 2
- All ages
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Vanderbilt Breast Center at One Hundred Oaks · Vanderbilt University/Ingram Cancer Center
- Registry record
- NCT05564377 · updated
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Pliant Therapeutics, Inc.
- Study site
- Tennessee Oncology
- Registry record
- NCT06270706 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Nashville, TN on ClinicalTrials.gov.
Lung cancer studies recruiting in Nashville
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- IDEAYA Biosciences
- Study site
- Sarah Cannon Research Institute
- Registry record
- NCT07277413 · updated
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Eikon Therapeutics
- Study site
- Tennessee Oncology
- Registry record
- NCT07365319 · updated
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Astellas Pharma Global Development, Inc.
- Study site
- Tennessee Oncology, PLLC
- Registry record
- NCT07730021 · updated
A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Pfizer
- Study sites
- SCRI Oncology Partners · Sarah Cannon Research Institute - Pharmacy
- Registry record
- NCT07903415 · updated
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Pfizer
- Study sites
- SCRI Oncology Partners · Sarah Cannon Research Institute - Pharmacy
- Registry record
- NCT03460977 · updated
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Phase 3
- Ages 18 to 100
- All sexes
- Sponsor
- Amgen
- Study site
- Sarah Cannon Research Institute
- Registry record
- NCT05920356 · updated
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Boehringer Ingelheim
- Study site
- Sarah Cannon Research Institute-Nashville-48456
- Registry record
- NCT04886804 · updated
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Bayer
- Study site
- Tennessee Oncology - Nashville Centennial Clinic
- Registry record
- NCT05099172 · updated
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- OSE Immunotherapeutics
- Study sites
- Greco-Hainsworth Tennessee Oncology Centers for Research (GHCR) - Corporate · Tennessee Oncology - Nashville - St. Thomas West Clinic
- Registry record
- NCT06472245 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Nashville, TN on ClinicalTrials.gov.
Prostate cancer studies recruiting in Nashville
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
- Phase 2
- Ages 18 and older
- Male participants
- Sponsor
- VA Office of Research and Development
- Study site
- Tennessee Valley Healthcare System Nashville Campus, Nashville, TN
- Registry record
- NCT05011383 · updated
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- SCRI Oncology Partners ( Site 7000)
- Registry record
- NCT06136624 · updated
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Vanderbilt University/Ingram Cancer Center
- Registry record
- NCT03866382 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Nashville, TN on ClinicalTrials.gov.
Melanoma studies recruiting in Nashville
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
- Phase 3
- Ages 75 and older
- All sexes
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Study site
- Vanderbilt University/Ingram Cancer Center
- Registry record
- NCT07068074 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Nashville, TN on ClinicalTrials.gov.
Lymphoma studies recruiting in Nashville
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- Tennessee Oncology
- Registry record
- NCT06806033 · updated
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Nurix Therapeutics, Inc.
- Study site
- SCRI Oncology Partners
- Registry record
- NCT07221500 · updated
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Nurix Therapeutics, Inc.
- Study site
- SCRI Oncology Partners
- Registry record
- NCT07520006 · updated
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- SCRI Oncology Partners ( Site 7000)
- Registry record
- NCT06717347 · updated
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- SCRI Oncology Partners ( Site 7002)
- Registry record
- NCT06890884 · updated
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- Henry-Joyce Cancer Clinic ( Site 0115) · SCRI Oncology Partners ( Site 0100)
- Registry record
- NCT07519772 · updated
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- SCRI Oncology Partners ( Site 7000)
- Registry record
- NCT07634471 · updated
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- Ages 1 to 30
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- The Children's Hospital at TriStar Centennial · Vanderbilt University/Ingram Cancer Center
- Registry record
- NCT04546399 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- The Children's Hospital at TriStar Centennial · Vanderbilt University/Ingram Cancer Center
- Registry record
- NCT05675410 · updated
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Regeneron Pharmaceuticals
- Study site
- Vanderbilt University Medical Center
- Registry record
- NCT06091254 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Nashville, TN on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in Nashville
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- Phase 2
- Ages 12 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Vanderbilt University Medical Center ( Site 0107)
- Registry record
- NCT04924075 · updated
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Incyte Corporation
- Study sites
- Investigative Site US039 · Investigative Site US060 · Investigative Site US070
- Registry record
- NCT07522073 · updated
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Verastem, Inc.
- Study site
- Sarah Cannon Research Institute
- Registry record
- NCT07644559 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Nashville, TN on ClinicalTrials.gov.
Ask about studies near Nashville
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections